USD 573.42 billion
Report ID:
SQMIG35J2043 |
Region:
Global |
Published Date: February, 2024
Pages:
224
|Tables:
92
|Figures:
76
Microbiome Market size was valued at USD 743.21 Billion in 2023 and is poised to grow from USD 963.27 Billion in 2024 to USD 7671.11 Billion by 2032, growing at a CAGR of 29.61% during the forecast period (2025-2032).
Microbiome is a collection of microorganisms that live on and within our bodies. The United States National Institutes of Health (NIH) started the Human Microbiome Project to increase understanding of the microbial flora involved in human health and disease. The market is expanding as a result of factors such as an increase in the number of strategic alliances for microbiome therapies for R&D, product development, the anticipated introduction of innovative medications, and portfolio enhancement. For example, Hudson Institute and BiomeBank announced a four-year agreement in January 2022 to develop and discover microbial treatments. Furthermore, the increasing prevalence of target diseases is driving up demand for microbiome therapies.
US Microbiome Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 573.42 billion
Largest Segment
robiotics
Fastest Growth
robiotics
Growth Rate
29.61% CAGR
To get more reports on the above market click here to Buy The Report
Global Microbiome market is segmented based on product, application, distribution channel and region. Based on the product, the Microbiome Market is segmented into probiotics, feed prebiotics, symbiotics, others. Based on the application, the Microbiome Market is segmented into therapeutics, diagnostics, nutrition and dietics, others. Based on the distribution channel, the Microbiome Market is segmented into retail pharmacies, online pharmacies, supermarkets and hypermarket. Based on the region, the Microbiome Market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.
Microbiome Market Analysis by Application
Based on the application, the market is segmented into therapeutics, diagnostics, nutrition and dietics, others. Among these, the digital therapeutics segment of the market is projected to hold the most substantial share in the market. The increase in funding for R&D into microbiome-based medicines around the world is a major element driving the expansion of this application area. Furthermore, technological developments, an increase in the number of clinical trials for the diagnostics segment, and increased collaborations between leading market players and research institutes are all boosting market expansion.
To get detailed analysis on other segments, Request For Free Sample Report
North America is expected to account for the lion's share of the global human microbiome market. The region's domination is due to the rising prevalence of lifestyle problems and advances in next-generation sequencing. For example, Illumina Inc., a major player in the United States, claims that the introduction of next-generation sequencing enables various high-profile joint projects, like the Human Microbiome Project and MetaHIT. Using Next Generation Sequencing as a basic tool, these projects have published a wide range of data on the human microbiome.
Europe is likely to increase its market share during the forecast period as a result of extensive research and development of novel human microbiome applications. According to NCBI, new microbiome programmes such as ONCOBIOME, MICROB-predict, and GEMMA are focused on oncology, mapping of human microbiota, and autistic spectrum disorders, respectively, and are expected to boost market expansion in this region in March 2020.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Microbiome Market Driver
Human gut microbiomes play a significant impact in the efficacy of medicinal drugs. Several studies have demonstrated that the appropriate balance of microorganisms in the human body can help treat a variety of illnesses. This link between bacteria and specific disease states could open up new avenues for medication development (or vaccine manufacturers). Because microbes are rich in enzymes, they can be exploited in a variety of therapeutic applications, such as the search for novel medicines.
Microbiome treatment has grown in popularity. Over a ten-year period, the National Institutes of Health (NIH) spent USD 215 million on the Human Microbiome Project (HMP) and USD 728 million on extramural human microbiome research initiatives outside of the HMP. Similarly, the European Commission established the Metagenomics of the Human Intestinal Tract (MetaHIT) initiative, which is primarily concerned with gut microbes. This project received USD 15 million investments from 2008 - 2012. MetaCardis (Metagenomics in Cardiometabolic Disorders), a large EU-funded research project that explored the function of gut bacteria in cardiometabolic diseases, received a USD 14 million (EUR 12 million) investment from 2012 to 2018. (CMDs). Similarly, Horizon 2020 is one of the largest EU R&I projects, with about USD 96.9 million (€80 billion) available over seven years (2014 to 2020).
Microbiome Market Restraint
Probiotics have not been approved by the FDA as a live biotherapeutic product (a biological product other than a vaccine that contains live organisms used to prevent or treat a disease or condition in humans). Nonetheless, FDA-regulated foods containing probiotics, including dietary supplements, are legally available; however, these items cannot be legitimately advertised to cure, mitigate, treat, or prevent any diseases.
Probiotic supplements are heavily promoted in retail stores and on the Internet. Although no probiotic has been licenced by the FDA for therapeutic reasons as of yet, some are now undergoing clinical trials and may be sold as biologics or other medications in the near future. The existing FDA regulatory regulations do not apply to probiotics. Given the future market potential for probiotics, it is possible that the FDA will issue regulations requiring research/clinical studies. It has been suggested that probiotics with drug claims be subjected to the same standards as other medications under the Abbreviated New Drug Application (ANDA) procedure. This will also allow probiotics to be exempted from Phase I studies, the first step in the research process. This may hamper the growth of the human microbiome market since big investors will have to invest more in R&D.
Request Free Customization of this report to help us to meet your business objectives.
The market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies in order to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D in order to supply industries with the most efficient and cost-effective solutions.
Microbiome Market Top Player’s Company Profiles
Microbiome Market Recent Developments
With several small innovative players in the market, there are several high-growth opportunities for key stakeholders to buy out companies in order to study microbiomes in the hope of identifying new drugs and drug targets for various indications such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders are working on strategic collaborations and partnerships to expand their product pipelines through well-organized R&D approaches. Many alliances and partnerships involving large corporations have occurred in the recent two years.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to our analysis, Global Microbiome market is segmented based on product, application, distribution channel and region. Based on the product, the probiotics segment is projected to hold a significant share in the market. Based on the application, the therapeutics segment is projected to hold a significant share in the market. Based on the distribution channel, the retail pharmacies segment is projected to hold a significant share in the market. Based on the region, North America region holds a substantial market share.
Report Metric | Details |
---|---|
Market size value in 2019 | USD 573.42 billion |
Market size value in 2031 | USD 5918.61 billion |
Growth Rate | 29.61% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Microbiome Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Microbiome Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Microbiome Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Microbiome Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35J2043
sales@skyquestt.com
USA +1 351-333-4748